Marius Pharmaceuticals Applauds FDA’s Proposed Testosterone Labeling Updates as a Turning Point for Men’s Health

▤ Summary

Marius Pharmaceuticals is backing the FDA’s proposed testosterone labeling updates as a major shift for men’s health. The company says the changes align prescribing information with newer clinical evidence and remove older language about age-related low testosterone, prostate cancer risk, and enlarged prostate warnings. Marius highlights its role in advancing the earlier removal of the cardiovascular boxed warning and in pushing regulators to revisit the remaining label restrictions. The update strengthens the company’s position in testosterone therapy and supports broader physician and patient confidence in evidence-based hormone care.

▦ Linked Companies